Micafungina Accordpharma (Micafungin)

Micafungin blocks the enzyme β‑(1,3)‑D‑glucan synthase, preventing the formation of β‑(1,3)‑D‑glucan, a vital component of the fungal cell wall. Without this polymer, the cell wall weakens, leading to osmotic instability, cell lysis and death of susceptible Candida species.

The dose of Micafungina is determined by the prescribing clinician based on the type and severity of infection, patient weight, and renal or hepatic function. No fixed regimen is provided here; the prescriber sets the appropriate dosing schedule.

Safety data for micafungin in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any potential risk to the fetus or infant, and treatment decisions should involve an obstetric specialist.

To order Micafungina, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Micafungina belongs to the echinocandin class, which targets the fungal cell wall, whereas azoles inhibit ergosterol synthesis and polyenes bind directly to ergosterol. Echinocandins are generally well‑tolerated, have fewer drug‑drug interactions, and are preferred for invasive Candida infections, especially in patients with azole resistance or intolerance.

Micafungina should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vials in their original packaging until use to maintain stability and sterility.

Micafungina is given as an intravenous infusion, typically diluted in a compatible IV fluid and administered over about 60 minutes under medical supervision. The infusion rate and duration are set by the treating physician based on patient condition.

The most serious risks include severe hypersensitivity reactions such as anaphylaxis, acute hepatic failure, life‑threatening infusion‑related events, and rare dermatologic emergencies like Stevens‑Johnson syndrome. Prompt recognition and discontinuation are essential if these events occur.

Micafungina is contraindicated in patients with a known hypersensitivity to micafungin or any other echinocandin. It should also be avoided in individuals with severe hepatic impairment where the risk of liver toxicity outweighs potential benefits.